CDTX Logo

Cidara Therapeutics, Inc. (CDTX) 

NASDAQ
Market Cap
$92.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
234 of 776
Rank in Industry
135 of 433

Largest Insider Buys in Sector

CDTX Stock Price History Chart

CDTX Stock Performance

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its …

Insider Activity of Cidara Therapeutics, Inc.

Over the last 12 months, insiders at Cidara Therapeutics, Inc. have bought $105,680 and sold $75,650 worth of Cidara Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Cidara Therapeutics, Inc. have bought $207,124 and sold $55,479 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Stein Jeffrey (President & CEO) — $105,680.

The last purchase of 8,000 shares for transaction amount of $105,680 was made by Stein Jeffrey (President & CEO) on 2024‑06‑07.

List of Insider Buy and Sell Transactions, Cidara Therapeutics, Inc.

2024-09-11SaleChief Medical Officer
924
0.0128%
$11.64$10,752+2.60%
2024-09-11SaleCHIEF SCIENTIFIC OFFICER
909
0.0126%
$11.64$10,580+2.60%
2024-06-07PurchasePresident & CEO
8,000
0.1804%
$13.21$105,680-8.61%
2024-03-11SaleChief Medical Officer
20,662
0.0231%
$0.67$13,839-5.33%
2024-03-11SaleCHIEF SCIENTIFIC OFFICER
21,029
0.0235%
$0.67$14,085-5.33%
2024-03-11SaleCFO & CBO
18,931
0.0212%
$0.67$12,680-5.33%
2024-03-11SaleCOO & CLO
20,473
0.0229%
$0.67$13,713-5.33%
2023-09-11SaleChief Medical Officer
18,793
0.0205%
$0.95$17,810-26.20%
2023-09-11SaleCHIEF SCIENTIFIC OFFICER
18,469
0.0202%
$0.95$17,509-26.20%
2023-08-14PurchaseCHIEF SCIENTIFIC OFFICER
10,000
0.0118%
$0.97$9,700-20.54%
2023-08-08PurchasePresident & CEO
50,000
0.0566%
$0.96$47,885-22.05%
2023-03-27PurchasePresident & CEO
50,000
0.0653%
$1.04$51,855-9.78%
2023-03-13SaleChief Medical Officer
7,203
0.0081%
$1.53$11,021-45.66%
2023-03-13SaleCHIEF SCIENTIFIC OFFICER
7,562
0.0085%
$1.53$11,570-45.66%
2023-03-13SaleCFO & CBO
6,648
0.0075%
$1.53$10,171-45.66%
2023-03-13SaleCOO & CLO
4,329
0.0049%
$1.53$6,623-45.66%
2023-01-12SaleCHIEF SCIENTIFIC OFFICER
11,814
0.015%
$1.20$14,177-13.33%
2022-09-19SaleCFO & CBO
15,642
0.0226%
$0.77$12,035+38.16%
2022-09-12SaleChief Medical Officer
18,478
0.0264%
$0.68$12,656+51.03%
2022-09-12SaleChief Operating Officer
16,199
0.0232%
$0.68$11,095+51.03%

Insider Historical Profitability

<0.0001%
Shah PreetamCFO & CBO
227210
3.2282%
$13.1313<0.0001%
Stein JeffreyPresident & CEO
24580
0.3492%
$13.13160<0.0001%
Sandison TaylorChief Medical Officer
23067
0.3277%
$13.1325+18.64%
Tari LeslieCHIEF SCIENTIFIC OFFICER
17788
0.2527%
$13.1317
BIOTECH TARGET N V10 percent owner
2295272
32.6114%
$13.1310<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bvf Inc Il$6.31B150.416.86M0%+$046.21
The Vanguard Group$3.08B73.363.35M0%+$00.06
Renaissance Technologies$2.35M56.012.55M+41.77%+$692,701.18<0.01
Alethea Capital Management LLC$1.47B35.041.6M-1.79%-$26.84M92.4
Point72 Asset Management$1.15B27.41.25M0%+$01.68
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.